Azenta Life Sciences Partners with UK Biocentre for Automation

Innovative Storage Solutions from Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) has solidified its reputation as a leading technology provider with a significant new partnership with UK Biocentre. The Biocentre is renowned for its dedication to preserving vital sample collections on a large scale. This collaboration will see the installation of the cutting-edge BioArc Ultra automated storage system, which aims to enhance research efforts significantly.

Expanding Storage Capacity for Advanced Research

The introduction of BioArc Ultra comes to complement the existing seven BioArc™ Flex™ automated sample storage systems already implemented at UK Biocentre. These systems work together to support some of the most prestigious health research projects, including the significant national initiative aimed at improving health outcomes for millions.

High Efficiency and Capacity

UK Biocentre’s facility, designed to accommodate extensive sample management processes, currently has a storage capacity of over 35 million samples. The new BioArc Ultra will increase this capacity by an additional 16 million samples. This fully automated storage unit operates at -80°C, ensuring optimal conditions for sensitive biological samples while achieving an impressive capability of handling up to 9 million picks annually.

Commitment to Sustainability and Efficiency

One of the most notable features of the BioArc Ultra is its commitment to operational efficiency. The system is designed to reduce necessary footprint, lower labor costs, and minimize energy expenditures compared to other available systems. With an eco-friendly refrigeration system boasting zero ozone depletion and global warming potential, it aligns perfectly with UK Biocentre's mission of advancing sustainable practices in scientific research.

Enhancing Research for Health Innovations

UK Biocentre aims to utilize BioArc Ultra's storage capabilities to support a massive health study involving up to 5 million participants. This effort is focused on innovating new methodologies for preventing, diagnosing, and treating various diseases, making the collaboration crucial to healthcare advancements.

Leadership Insight from UK Biocentre

Dr. Tony Cox OBE, the Chief Executive Officer of UK Biocentre, noted, "The BioArc Ultra ensures UK Biocentre remains at the forefront of large-scale sample storage innovation while fulfilling our mission to reduce the environmental impact of vital clinical and life science research. We are proud to partner with Azenta Life Sciences to bring this unique offering to the UK, enabling us to maximize the potential of every sample."

A Thriving Partnership

Echoing the sentiments of his colleague, Alex Esmon, the Vice President and General Manager of Global Products at Azenta Life Sciences, articulated, "We are excited to support UK Biocentre with the advanced automation sample storage capabilities of the BioArc Ultra. The addition of this system will significantly enhance our ability to facilitate breakthroughs, ensuring sample integrity while streamlining workflows and supporting sustainability."

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a prominent provider of life sciences solutions worldwide, focusing on accelerating impactful breakthroughs and therapies to the market. With an extensive portfolio of reliable cold-chain sample management solutions and multiomics services catered to diverse sectors, including drug development and clinical research, Azenta serves leading institutions in the pharmaceutical, biotechnology, and healthcare industries globally.

About the UK Biocentre

UK Biocentre stands out as a respected authority in sample management and high-capacity bioprocessing. By supporting significant biomedical, pharmaceutical, and clinical research initiatives, it facilitates advancements in the field of life sciences, demonstrating a commitment to delivering excellent quality and innovative solutions that drive significant scientific progress.

Frequently Asked Questions

What is the significance of the BioArc Ultra for UK Biocentre?

The BioArc Ultra enhances UK Biocentre's sample storage capabilities by adding capacity for 16 million samples and optimizing workflow efficiency.

How does the BioArc Ultra contribute to sustainability?

The system features an eco-friendly refrigeration mechanism, supporting lower energy costs and needs while reducing carbon emissions.

What is Azenta Life Sciences known for?

Azenta Life Sciences specializes in providing innovative life sciences solutions including cold-chain sample management and multiomics services.

What major projects will benefit from the BioArc Ultra?

The BioArc Ultra will support significant health programs like the 'Our Future Health' initiative involving up to 5 million participants.

Who leads the UK Biocentre?

Dr. Tony Cox OBE is the Chief Executive Officer of UK Biocentre, overseeing its mission to push the boundaries of research and sustainability.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.